TY - JOUR
T1 - Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy
T2 - ACTG A5248
AU - Andrade, Adriana
AU - Rosenkranz, Susan L.
AU - Cillo, Anthony R.
AU - Lu, Darlene
AU - Daar, Eric S.
AU - Jacobson, Jeffrey M.
AU - Lederman, Michael
AU - Acosta, Edward P.
AU - Campbell, Thomas
AU - Feinberg, Judith
AU - Flexner, Charles
AU - Mellors, John W.
AU - Kuritzkes, Daniel R.
N1 - Funding Information:
Financial support. This work was supported by grants to the AIDS Clinical Trials Group (U01 AI068636, AI069472, AI68634, AI069465, AI069494, and AI69450), including ACTG support of the Harvard and University of Pittsburgh Virology Specialty Laboratories, the Harvard University Center for AIDS Research (P30 AI060354), and the Statistical and Data Management Center (UM1 AI068634), funded by the National Institute of Allergy and Infectious Diseases; and by Clinical and Translational Science Centers (UL1 RR 025005, RR025780, and RR025780), funded by the National Center for Research Resources. Merck provided drug for this study, as well as financial support for plasma HIV-1 RNA determinations.
PY - 2013/9/15
Y1 - 2013/9/15
N2 - Objective. The goal of this study was to define viral kinetics after initiation of raltegravir (RAL)-based antiretroviral therapy (ART).Methods. ART-naive patients received RAL, tenofovir disoproxil fumarate, and emtricitabine for 72 weeks. Human immunodeficiency virus type 1 (HIV-1) RNA were measured by ultrasensitive and single-copy assays, and first (d1)-, second (d2)-, and, third (d3)-phase decay rates were estimated by mixed-effects models. Decay data were compared to historical estimates for efavirenz (EFV)-and ritonavir/lopinavir (LPV/r)-based regimens.Results. Bi-and tri-exponential models for ultrasensitive assay (n = 38) and single-copy assay (n = 8) data, respectively, provided the best fits over 8 and 72 weeks. The median d1 with ultrasensitive data was 0.563/day (interquartile range [IQR], 0.501-0.610/day), significantly slower than d1 for EFV-based regimens [P <. 001]). The median duration of d1 was 15.1 days, transitioning to d2 at an HIV-1 RNA of 91 copies/mL, indicating a longer duration of d1 and a d2 transition at lower viremia levels than with EFV. Median patient-specific decay estimates with the single-copy assay were 0.607/day (IQR, 0.582-0.653) for d1, 0.070/day (IQR, 0.042-0.079) for d2, and 0.0016/day (IQR, 0.0005-0.0022) for d3; the median d1 duration was 16.1 days, transitioning to d2 at 69 copies/mL. d3 transition occurred at 110 days, at 2.6 copies/mL, similar to values for LPV/r-based regimens.Conclusions. Models using single-copy assay data revealed 3 phases of decay with RAL-containing ART, with a longer duration of first-phase decay consistent with RAL-mediated blockade of productive infection from preintegration complexes.Clinical Trials Registration. NCT00660972.
AB - Objective. The goal of this study was to define viral kinetics after initiation of raltegravir (RAL)-based antiretroviral therapy (ART).Methods. ART-naive patients received RAL, tenofovir disoproxil fumarate, and emtricitabine for 72 weeks. Human immunodeficiency virus type 1 (HIV-1) RNA were measured by ultrasensitive and single-copy assays, and first (d1)-, second (d2)-, and, third (d3)-phase decay rates were estimated by mixed-effects models. Decay data were compared to historical estimates for efavirenz (EFV)-and ritonavir/lopinavir (LPV/r)-based regimens.Results. Bi-and tri-exponential models for ultrasensitive assay (n = 38) and single-copy assay (n = 8) data, respectively, provided the best fits over 8 and 72 weeks. The median d1 with ultrasensitive data was 0.563/day (interquartile range [IQR], 0.501-0.610/day), significantly slower than d1 for EFV-based regimens [P <. 001]). The median duration of d1 was 15.1 days, transitioning to d2 at an HIV-1 RNA of 91 copies/mL, indicating a longer duration of d1 and a d2 transition at lower viremia levels than with EFV. Median patient-specific decay estimates with the single-copy assay were 0.607/day (IQR, 0.582-0.653) for d1, 0.070/day (IQR, 0.042-0.079) for d2, and 0.0016/day (IQR, 0.0005-0.0022) for d3; the median d1 duration was 16.1 days, transitioning to d2 at 69 copies/mL. d3 transition occurred at 110 days, at 2.6 copies/mL, similar to values for LPV/r-based regimens.Conclusions. Models using single-copy assay data revealed 3 phases of decay with RAL-containing ART, with a longer duration of first-phase decay consistent with RAL-mediated blockade of productive infection from preintegration complexes.Clinical Trials Registration. NCT00660972.
KW - ACTG A5160s
KW - ACTG A5166s
KW - ACTG A5248
KW - Roche ultrasensitive assay
KW - raltegravir
KW - single copy assay
KW - viral decay
UR - http://www.scopus.com/inward/record.url?scp=84883206439&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883206439&partnerID=8YFLogxK
U2 - 10.1093/infdis/jit272
DO - 10.1093/infdis/jit272
M3 - Article
C2 - 23801609
AN - SCOPUS:84883206439
SN - 0022-1899
VL - 208
SP - 884
EP - 891
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 6
ER -